University of Adelaide researchers will investigate if they can target proteins to divert cells that cause multiple sclerosis (MS) from entering the brain.
The potential outcomes of the three-year study could be life-changing for more than 33,000 Australians, and 2.8 million people worldwide, who are currently living with the chronic autoimmune disease.
Research Fellow, Dr Iain Comerford, is leading the study, which has been supported by MS Australia.
“How cells of the immune system enter the brain to cause disease in conditions like MS is not completely known,” Dr Comerford said.
“Drugs that can block this are likely to be useful new treatments.
“We are testing whether a combination of three proteins that are used by cells of the immune system to guide their migration can be targeted to prevent these cells from accessing the brain in a model of MS.
“We have identified that this combination of proteins is specifically present on inflammatory immune cells that enter the brain.”
“This research is important because if it is successful then it could lead to the development of new drugs that can better treat MS.”Dr Iain Comerford, Research Fellow, University of Adelaide.
The researchers will test the role of these proteins in guiding migration of inflammatory immune cells into the brain using two strategies.
“We will use mice we have engineered that cannot make these three proteins to test whether these proteins are important for T cell migration into the brain,” Dr Comerford said.
“Second, we will use drugs that specifically target these proteins to block their function.
“We will test if we can block these proteins with these drugs to prevent T cells entering the brain in MS.
“This research is important because if it is successful then it could lead to the development of new drugs that can better treat MS.”
The study has received $246,953 in funding from MS Australia as part of the 2023 round of 22 grants nationwide.
The latest study is an extension of previous research led by Dr Comerford that aims to .
A recent report discovered that , with the number of people diagnosed from 2017 to 2021 increasing sharply by 30 per cent – 25,600 to 33,335.
